Wall Street Zen upgraded shares of Celcuity (NASDAQ:CELC – Free Report) from a strong sell rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.
Several other equities research analysts also recently weighed in on CELC. Guggenheim started coverage on Celcuity in a report on Friday, November 6th. They set a “buy” rating and a $169.00 price target for the company. Royal Bank Of Canada lowered shares of Celcuity to a “neutral” rating in a research report on Wednesday, October 28th. Zacks Research cut shares of Celcuity from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 13th. Needham & Company LLC dropped their price objective on shares of Celcuity from $140.00 to $134.00 and set a “buy” rating on the stock in a research note on Wednesday, September 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Tuesday, September 1st. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $151.79.
View Our Latest Stock Analysis on Celcuity
Celcuity Stock Down 5.9%
Celcuity stock opened at $60.57 on Friday. Celcuity has a twelve month low of $53.54 and a twelve month high of $151.02. The stock has a 50 day moving average of $71.77 and a two-hundred day moving average of $97.96. The company has a quick ratio of 8.93, a current ratio of 14.62 and a debt-to-equity ratio of 6.04.
Celcuity (NASDAQ:CELC – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, beating the consensus estimate of ($1.51) by $0.30. As a group, research analysts expect that Celcuity will post -5.01 EPS for the current fiscal year.
Institutional Investors Weigh In On Celcuity
A number of institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. raised its stake in shares of Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after buying an additional 86 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Celcuity by 15.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock valued at $99,000 after buying an additional 124 shares during the period. Integrity Alliance LLC. boosted its stake in shares of Celcuity by 2.2% in the third quarter. Integrity Alliance LLC. now owns 11,868 shares of the company’s stock valued at $944,000 after buying an additional 250 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Celcuity by 1.0% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 31,092 shares of the company’s stock valued at $3,253,000 after buying an additional 297 shares in the last quarter. Finally, IFP Advisors Inc boosted its stake in shares of Celcuity by 42.6% in the third quarter. IFP Advisors Inc now owns 995 shares of the company’s stock valued at $79,000 after buying an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.
See Also
- Five stocks we like better than Celcuity
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
